Recursion Pharmaceuticals (RXRX) Consolidated Net Income (2020 - 2026)

Recursion Pharmaceuticals has reported Consolidated Net Income for 7 years, with the latest figure at -$117.5 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 41.97% year-over-year to -$117.5 million; the trailing twelve-month figure through Mar 2026 stood at -$559.8 million (up 2.61% YoY), and the FY2025 full-year result was -$644.8 million, down 39.06% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$117.5 million, down from -$108.1 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$56.0 million in Q1 2022, with the low at -$202.5 million in Q1 2025.
• Historically, Consolidated Net Income has averaged -$105.9 million across 5 years, with a median of -$93.0 million in 2023.
• Annual changes were most pronounced in 2025 — Consolidated Net Income slumped 121.6% — and 2026, when it soared 41.97%.
• Recursion Pharmaceuticals' Consolidated Net Income stood at -$61.0 million in 2022, then plunged by 52.5% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then jumped by 39.56% to -$108.1 million in 2025, then slipped by 8.68% to -$117.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$117.5 million (Q1 2026), -$108.1 million (Q4 2025), and -$162.3 million (Q3 2025), per Business Quant data.